An internal standard for the quantification of tranexamic acid
Related Products
Unlabeled Version(s)
19193Tranexamic Acid
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Tranexamic Acid-13C2,15N

Item No. 28804

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
trans-4-(amino-15N-methyl-13C)-cyclohexanecarboxylic-13C acid
CAS Number
1292837-95-6
Synonyms
  • AMCA-13C2,15N
  • TXA-13C2,15N
Molecular Formula
C6[13C2]H15[15N]O2
Formula Weight
160.2
Purity
≥95%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
Water: slightly soluble
SMILES
O[13C]([C@H]1CC[C@H]([13CH2][15NH2])CC1)=O
InChi Code
InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-/i5+1,8+1,9+1
InChi Key
GYDJEQRTZSCIOI-MWCUNNTJSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $528

    Add
    Product Description

    Tranexamic acid 13C2,15N is intended for use as an internal standard for the quantification of tranexamic acid (Item No. 19193) by GC- or LC-MS. Tranexamic acid is an inhibitor of fibrinolysis that inhibits the interaction of plasmin with fibrin (IC50 = 3.1 µM in isolated human plasma).1 It reduces increases in the expression of the profibrogenic genes Timp1 and Col1a1, but not Itgb6, Tgfβ1, or Tgfβ2, and increases in hepatic protein levels of cytokeratin 19 (CK19) and type I collagen induced by α-naphthylisothiocyanate (AINT) after 28 days in a mouse model of chronic bile duct injury.2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Boström, J., Grant, J.A., Fjellström, O., et al. Potent fibrinolysis inhibitor discovered by shape and electrostatic complementarity to the drug tranexamic acid. J. Med. Chem. 56(8), 3273-3280 (2013).

    2. Joshi, N., Kopec, A.K., Towery, K., et al. The antifibrinolytic drug tranexamic acid reduces liver injury and fibrosis in a mouse model of chronic bile duct injury. J. Pharmacol. Exp. Ther. 349(3), 383-392 (2014).